As a result, SERPINE1 was identified as the key target of norcantharidin intervention in GC, consistent with network pharmacology and molecular docking findings identifying SERPINE1 as one of norcantharidin’s targets. This evidence concerns the gene SERPINE1 and gastric cancer.